ArticleMalaria journal2025
Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria in Liberia, 2022-2023.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Phytochemical synergy in artemisia annua herbal tea against malaria: a systematic review of its efficacy and safety in the context of emerging Pfkelch13 resistance.Infectious diseases of poverty · 2026Pooled it
- Efficacy of artemether-lumefantrine combination for the treatment of uncomplicated Plasmodium falciparum malaria after 16 years of its introduction into Ghana's antimalarial medicines policy.Malaria journal · 2026Article
- Population pharmacokinetics of lumefantrine in pregnant and non-pregnant Nigerian women receiving efavirenz-based antiretroviral therapy.European journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArtemether-lumefantrine (AL) is currently the first-line treatment for uncomplicated Plasmodium falciparum malaria in Liberia. To ensure antimalarial treatments are effective, the World Health Organization (WHO) recommends routinely testing the efficacy of oral artemisinin-based combination therapy (ACT) for uncomplicated malaria using therapeutic efficacy studies (TES) every two years. The most recent TES in Liberia conducted from December 2017 to May 2018 reported a PCR-corrected adequate clinical and parasitological response (ACPR) of 90.2% in Bensonville and 92.7% in Saclepea for artesunate-amodiaquine (ASAQ), and 100% in Kakata and Sinje for AL. Due to these findings AL was prioritized over ASAQ as the first-line ACT in Liberia. However, ASAQ is commonly available in Liberia and remains highly efficacious in other West African countries.
methodsThe therapeutic efficacy of AL and ASAQ were evaluated using the standard WHO TES protocol in Saclepea and Sinje, Liberia, from August 2022 to July 2023. Eligible children aged 6 - 59 months with uncomplicated P. falciparum malaria infection (2,000-200,000 asexual parasites/μL) were recruited, treated with AL or ASAQ at each site, and monitored clinically and parasitologically for 28 days.
resultsA total of 1,630 children were screened for eligibility and 305 were enrolled. Among enrolled children, 152 were treated with AL (78 in Sacleapea and 74 in Sinje) and 153 were treated with ASAQ (77 in Sacleapea and 76 in Sinje). Of the enrolled children, 299 (98%) reached a study endpoint or completed the 28 days of follow up. No adverse events were reported for either AL or ASAQ during the study period. The proportion of participants with parasitaemia on day 3 of follow up was 1.3% (2/153) for ASAQ, and 0% (0/151) treated with AL. The PCR-corrected ACPR at day 28 was 100% in Saclepea and 95.9% (95CI 88.0%-98.7%) in Sinje for AL, and 100% in Saclepea and 94.4% (95CI 85.9%-97.9%) in Sinje for ASAQ.
conclusionThe PCR-corrected ACPR efficacy greater than the 90% WHO threshold, and day 3 slide positivity rate demonstrate that AL and ASAQ are both effective treatments for uncomplicated malaria in Liberia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.